Bortezomib-Based GVHD Regimen Efficacious in MMUD RIC HSCT

Share this content:
(ChemotherapyAdvisor) – A novel short-course, bortezomib-based prophylaxis for graft-versus-host-disease (GVHD) in HLA-mismatched unrelated donor (MMUD) reduced intensity conditioning (RIC) hematopoietic stem-cell transplantation (HSCT) was safe and efficacious and offered “encouraging” survival results, according to a study in the Journal of Clinical Oncology online August 6.

“Importantly, bortezomib-based MMUD transplantation achieved clinical outcomes comparable to HLA-matched transplantation, along with enhancement of various immune reconstitution parameters,” noted John Koreth, MBBS, DPhil, Dana-Farber Cancer Institute, Boston, MA, and colleagues.

In the prospective phase 1/2 trial, 45 patients with hematologic malignancies undergoing MMUD RIC HSCT received bortezomib once daily on days 1, 4, and 7 following peripheral blood stem-cell infusion plus standard tacrolimus and methotrexate. Forty of the patients (89%) had 1-locus and 5 (11%) had 2-loci mismatches (HLA-A, -B, -C, -DRB1, or -DQB1); median follow-up was 36.5 months (range, 17.4 to 59.6 months).

Cumulative incidence of grade 2 to 4 acute GVHD was 22% (95% CI, 11%–35%) at 180 days; chronic GVHD was 29% (95% CI, 16%–43%) at 2 years. Two-year cumulative incidence of nonrelapse mortality (NRM) was 11% (95% CI, 4%–22%) and relapse, 38% (95% CI, 24%–52%). At 2 years, progression-free survival was 51% (95% CI, 36%–64%) and overall survival, 64% (95% CI, 49%–76%).

“Bortezomib-treated HLA-mismatched patients experienced rates of NRM, acute and chronic GVHD, and survival similar to those of contemporaneous HLA-matched RIC HSCT at our Institution,” they reported. Bortezomib also enhanced immune recovery, including CD8+ T-cell and natural killer cell reconstitution.

An accompanying article noted that based on these data, “bortezomib-based strategies can potentially join post-transplant cyclophosphamide and antithymocyte globulin as an effective strategy to prevent acute and chronic GVHD in the HLA-mismatch setting without ex vivo TCD [T-cell depletion]. However, only a prospective comparative trial of all these approaches will clarify the relative benefits of one strategy over another.”


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs